When Healthcare Turns Consumer: What Happens to the Pharmacist?
Retatrutide is an investigational Eli Lilly hormone receptor agonist that, as of February 2026, is in phase 3 clinical trials. It is not FDA approved. Yet numerous peptide companies are selling versions of it on Instagram under the caveat of 'research use only.' And consumers are buying it.
Since the product is for research use, and not human consumption, they are bypassing the FDA approval process, a physician’s prescription, and a pharmacist’s review. Why? Because the friction is lower. This isn’t about recklessness. It’s about incentives and consumer demands. And it’s a clear harbinger for the future of traditional pharmacy practice, that must not be ignored.
The Patient Era vs The Consumer Era
Since the beginning of the corner drug store, pharmacy has operated in an era of serving patients. A patient doesn’t have the answers, in fact they arrive looking for answers. Patients trust the system to give them what they need to cure their ills. They’re willing to pay, albeit under the fallacy the money they’re spending isn’t theirs but the insurance company’s money, for the system to give them these coveted answers. And, lastly, in a patient’s mindset they will even tolerate a mediocre experience and return despite repeated friction laden visits.
Alas, we are entering a consumer driven healthcare world. In stark contrast to “the patient” mindset, “a consumer” has researched their condition (e.g. “Dr. Google”, ChatGPT, Tom next door with a similar problem, etc.) and they arrive hyper-informed, believes they know what they need, is spending their own money, expects speed and transparency, and will not tolerate poor service twice.
The Financial Shift That Changes Everything
Healthcare’s financial landscape is adding rocket fuel to this fire. High-deductible health plans, ICHRAs, and cost sharing, by design, are shifting more first-dollar exposure to individuals (i.e. consumers).
When people spend their own money, their behavior changes. Convenience, speed, and access are no longer negotiable.
Retatrutide isn’t an anomaly. It’s a preview. Sure the FDA can issue sternly worded warning letters to egregious offenders (e.g. Darmerica inre retatrutide), but they undeniably cannot keep pace with the American consumers’ insatiable demands. So how does this impact the immediate job market or long-term career path for the traditional community pharmacist?
The Gatekeeper Problem
In the old patient-centric model, pharmacists were highly trusted healthcare professionals. Fast forward to the rapidly emerging consumer-centric model, and pharmacists can quickly gain the perception of access controllers and gatekeepers.
Even when clinically appropriate and exceptionally well-intended interactions around things like prior authorizations and other insurance limits feel like barriers. The $250 GLP-1 behind your counter…the one that requires a prescription? “No thank you, I buy mine online for $135 and my physician can’t even prescribe it for me.”
Heed these words: gatekeepers may or may not be tolerated but advisors are valued. If the community pharmacy market does not rapidly flex to acknowledge more of the patients at their counter are now consumers, the badge of gatekeeper will be yet another unfortunate dagger (i.e. declining reimbursements, PBM pressures, staffing shortages, escalating competition, etc.) to their pressure cooker world.
The Strategic Implications
Pharmacists working at jobs in traditional community pharmacy face three paths: remain in gatekeeping systems and prepare for disintermediation, design and/or move into advisory-forward models, or transition into non-traditional career paths that are better aligned for longevity in the future of a consumer-centric American healthcare.
The pharmacy profession is restructuring. Not all roles will carry equal leverage. Design your career accordingly.